NeoStem CEO Dr. Robin Smith’s Interview on Clear Channel Business Talk Radio Recap
Live Radio Interview Recap Michael Yorba DFW1190AM
NEW YORK, NY–(Dec 9, 2013) – NeoStem, Inc. (NASDAQ: NBS) (“NeoStem”), a leader in the emerging cellular therapy industry, today
announced that Dr. Robin L. Smith, Chairman and CEO, was interviewed live on Clear Channel’s “the Traders Network” DFW 1190AM hosted by Michael Yorba. The interview focused on explaining how NeoStem’s cell therapy product candidates work and what it means to the marketplace.
Dr. Smith went on talk about how there is a paradigm shift in medicine, using the cells of our bodies to treat disease and NeoStem’s leadership position in the industry. She said, “We have our own pipeline of products being developed to treat diseases, as well as manufacture cells for other companies to do the same.” NeoStem has seen Phase 1 results and is close to completing enrollment for a Phase 2 clinical trial.
When asked about NeoStem’s product candidates she said, “Our lead product candidate is in the cardiovascular space, treating patients after a heart attack to try to prevent the worsening of the heart muscle after the heart attack,” she explained. “Because if you are over the age of 45, 1 in 5 people will die within the year after the heart attack.”
Michael Yorba went on to ask how many people she thought could benefit from NeoStem’s product candidate, and she said over 10 million people have acute heart attacks, and over 22 million have congestive heart failure.
NeoStem was built through acquisition, obtaining key assets that allow them to be a leader in this emerging industry. The Company has raised over $180 million in the capital markets. They have been ranked number 1 for the second year running in the tri-state area in the Deloitte Technology Fast 500 list of fastest growing technology companies. Dr. Smith said, “It’s really exciting to be recognized in the industry among our peers. We feel really privileged.”
To hear the whole interview click on the archive stream link below.
Afterwards, Clear Channel Radio host Michael Yorba of the Traders Network was quoted saying “NeoStem is an obvious Biotech leader for years to come and what’s even better is it’s MADE IN THE USA.”
About Clear Channel
Clear Channel Media and Entertainment’s more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country. DFW1190AM.com Dallas-Ft. Worth, TX www.clearchannel.com
About Michael Yorba
Michael Yorba – featured host of Clear Channels DFW 1190AM in Dallas-Ft. Worth. For the past six years he has been integrally involved with the media industry in various capacities including building an IPTV Network, developing, producing and hosting a daily one hour talk show called Commodity Classics and then later The Traders Network, defined as an audience empowered interactive financial program that has been broadcast live on internet television and radio. His focus has been on derivative portfolio analysis for individual and corporate clients through the use of futures and futures options, managed funds, and Forex.
NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.www.neostem.com
A www.1800PublicRelations.com PR Event
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s research and development and clinical evaluation efforts as well as efforts towards commercialization of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company’s ability to successfully grow its contract development and manufacturing business. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company’s periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.